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Abstract  
Background: Despite simpler regimes than vitamin K antagonists(VKA) for stroke prevention in atrial 
fibrillation(AF), adherence(taking drugs as prescribed) and persistence(continuation of drugs) to direct oral 
anticoagulants(DOACs) are suboptimal, yet understudied in electronic health records(EHR).   
 
Objective: We investigated: (i)time trends at individual and system levels; (ii)risk factors for and associations 
between adherence and persistence. 
 
Methods: In UK primary care EHR(The Health Information Network; 2011-2016), we investigated adherence 
and persistence at 1-year for OACs in adults with incident AF. Baseline characteristics were analysed by 
OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed 
using Cox and logistic regression. Patterns of adherence and persistence were analysed.  
 
Results: Among 36652 individuals with incident AF, cardiovascular comorbidities(median CHA2DS2VASc 3) 
and polypharmacy(median number of drugs 6) were common. Adherence was 55.2%(95 CI 54.6-55.7), 
51.2%(50.6-51.8), 66.5%(63.7-69.2), 63.1%(61.8-64.4) and 64.7(63.2-66.1) for all OACs, VKA, dabigatran, 
rivaroxaban and apixaban. One-year persistence was 65.9%(65.4-66.5), 63.4%(62.8-64.0), 61.4%(58.3-
64.2), 72.3%(70.9-73.7) and 78.7%(77.1-80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. 
Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing 
comorbidity was associated with reduced risk of non-adherence and non-persistence, across all OACs. 
Overall rates of “primary non-adherence”(stopping after first prescription), “non-adherent non-persistence” 
and “persistent adherence” were 3.5%, 26.5% and 40.2%, differing across OACs. 
 
Conclusions: Adherence and persistence to OACs are low at one year with heterogeneity across drugs and 
over time, at individual and system levels. Better understanding of contributory factors will inform 
interventions to improve adherence and persistence across OACs in individuals and populations. 
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Key questions 
 
What is already known? 
 Despite proven efficacy for stroke prevention in atrial fibrillation, adherence and persistence are 
suboptimal for oral anticoagulants   
 Adherence and persistence are rarely studied together in the same population across all 
anticoagulants, taking into account all baseline factors in electronic health records.  
 
What does this study add? 
 This is the first study evaluating the time trends, predictive factors and associations between 
adherence and persistence of anticoagulants in atrial fibrillation in a population-based study in 
electronic health records 
 Persistence and adherence to OACs are relatively low at 1-year and there is heterogeneity across 
different OACs.  
 There are significant variations over the time that a patient is on a DOAC, and population-level time 
trends in adherence and persistence after new drugs (DOACs in this case) are introduced. 
 
How might this impact on clinical practice? 
 Interventions should focus on improving adherence and persistence together and across drugs. 
 These data may help to better understand the determinants of adherence and persistence, and to 
design and target interventions 
 
 
 
 
 
 
Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based 
study. 
 
Introduction 
For sixty years, vitamin K antagonists(VKA), mainly warfarin, dominated stroke prevention in atrial 
fibrillation(AF), the commonest arrhythmia globally(1, 2). Successive approval of four direct oral 
anticoagulants(DOACs: dabigatran(3), apixaban(4), rivaroxaban(5), edoxaban(6)) changed the landscape, 
with early adoption in guidelines(7, 8) and quality improvement initiatives(9). DOACs are often preferred over 
vitamin K antagonist(VKA) due to reduced international normalised ratio(INR) monitoring, but only if OAC 
services are fully decommissioned, and DOACs are taken appropriately. Paradoxically, removal of need for 
INR monitoring also removes additional patient-clinician engagement that encourages adherence(taking 
drugs as prescribed) and persistence(continuation of therapy)(10); both pertinent to OAC with a lifelong 
therapeutic indication.  
Despite its importance in the context of population ageing, declining cognitive function, multimorbidity and 
polypharmacy, adherence was unreported in trials of DOACs(3-6), despite short half-lives, particularly 
dabigatran and apixaban which require twice-daily dosing(11). Reported trial persistence was highest for 
dabigatran(79.3% at low-dose) and lowest for edoxaban(65.6% at high-dose)(3-6)(Web Table 1). All DOACs 
have proven efficacy compared with VKA, albeit at much lower time in therapeutic range(TTR) in trials than 
usual clinical practice, but “head-to-head” DOAC trial comparisons are unlikely. However, several studies 
have shown suboptimal adherence and persistence for DOACs in different countries and settings, even 
compared with VKA, and effective interventions are lacking(12-14). Underlying causes include factors at 
social, economic, health system, clinician and patient levels. Although all patient-level factors are not 
captured, electronic health records(EHR) allow population-level studies of adherence and persistence 
together across all DOACs in the same dataset, which are rare(13).  
Only one study to-date has considered all metrics of drug utilisation(“initiation”, “implementation” and 
“discontinuation”) together rather than “adherence” or “persistence” in isolation(15) for OAC in AF(13). Steps 
in drug utilisation may be described as the “prescription-persistence cascade”(from “recommendation” to 
“persistence”/“continuation”), estimable from EHR. For OAC in AF, the steps are “recommendation”(eligible 
for OAC); “initial prescription”( ≥1 OAC prescription), “dispensing”(no EHR data), “initiation by patient”(no 
EHR data), “adherence”/“implementation”(adherent to OAC), and “persistence”/“continuation”(persistent to 
OAC). Interaction between adherence and persistence is often overlooked, e.g. “persistent and non-
adherent”(i.e. continuing medications but not taking as prescribed) versus “non-persistent and non-
adherent”(i.e. discontinued medications and also not taking as prescribed).   
 
The UK has universal primary healthcare, enabling large-scale, representative datasets where uptake, 
adherence and persistence for different DOACs can be studied. We used The Health Improvement 
Network(THIN) database in the UK to investigate adherence and persistence for OACs in individuals with 
AF, focusing on: (i)time trends since DOAC introduction at health system level and after initiation in 
individuals; (ii)relative impact of sociodemographic and baseline risk factors and treatment characteristics; 
and (iii)associations between adherence and persistence.  
 
 
 
 
 
 
 
 
 
 
Methods 
The study conformed to STROBE recommendations(16) 
Data source 
The Health Improvement Network (THIN) database includes longitudinal, anonymised EHRs from over 500 
UK general practices using Visionsoftware(INPS, www.inps4.co.uk/), representative of the UK 
population(17).  
Study population 
Our retrospective cohort included individuals aged ≥18 years with first-ever, non-valvular AF diagnosis 
between January 2011 and December 2016 and first prescription of VKA/DOAC on or after the date of AF 
diagnosis. The date of first prescription became the index date. For inclusion, patients needed ≥90 days of 
follow-up. Individuals with ≥1 prescription of VKA/DOAC were eligible for inclusion in adherence/persistence 
analyses. Exclusion criteria were taking OAC for other indications(e.g. deep-vein thrombosis and pulmonary 
embolism). Follow-up was until outcome event, death, the patient leaving the database or the most recent 
data upload.  
Baseline covariates 
Baseline factors were assessed: demography(age, sex, Townsend Deprivation Index Quintile-Level 1 the 
least deprived category), comorbidities(heart failure, hypertension, diabetes mellitus, stroke/TIA, vascular 
disease, liver disease, hypercholesterolaemia-i.e. on statin and/or had hypercholesterolaemia), social 
history(alcohol misuse, smoking status), drug history(aspirin, statin, BP-lowering drugs and mean number of 
drugs including OAC, prescribed in ≤365 days until, but not including, the episode start date). CHA2DS2VASc 
(18) and “HASBLED-1” (rather than HASBLED(19), since INR and “labile INR” were not available) scores 
were calculated from available variables, and categorised based on current guidelines. 
Outcomes 
Outcomes were adherence to and persistence with OACs. Adherence was estimated by proportion of days 
covered(PDC) over the year following first prescription of VKA/DOAC, more accurately reflects patient 
behaviour and treatment continuity than other adherence measures(20):   
PDC=_________Number of days with drug supplied(up to maximum of 365)____________ 
Number of days between first and(last+30 days) prescription or 365 days*  
*(whichever is shorter) 
Each prescription was assumed to last 30 days, unless a new prescription was issued within 30 days, in 
which case the original prescription’s duration was assumed to equal the gap between the two prescriptions. 
Patients with only one OAC prescription were classed as ‘missing’ and not included in the estimation. Impact 
of varying PDC threshold to 70% and 90% was examined for all OACs. Adherence was defined as PDC>80% 
like previous studies(21) and produced more stable estimates. Individuals prescribed VKA/DOAC were 
deemed persistent until a prescription gap>90 days on that or an alternative OAC(‘switch’) in which case they 
were non-persistent, or there was no further longitudinal data(in which case persistence status was unknown 
beyond that time). For each DOAC, proportion of switching to VKA or another DOAC was analysed over 12-
months. Impact of varying prescription gaps to 60 and 120 days was examined for all OACs. Like previous 
studies(22), the 90-day prescription gap was used, providing more stable estimates. As prescription gaps 
lengthened, persistence improved more with VKA than DOACs(Web Table 3). 
Statistical analysis 
Baseline characteristics were analysed by OAC. If any OAC/DOAC group consisted of <100 individuals, 
sample size was deemed too low to undertake meaningful analysis. Persistence was estimated using Kaplan-
Meier product-limit estimator. Crude persistence for different OACs was estimated through survival life 
tables(adopting different prescription gaps) and ascertaining number and percentage(95% confidence 
intervals) of patients still in the study(i.e. persistent or uncensored) after 1 year. After stratification by 
adherence/persistence status at 12 months, baseline characteristics were determined. Chi-squared test and 
ANOVA test were used for categorical and continuous covariates respectively. Relative effects of OACs on 
non-adherence and non-persistence were modelled using univariable and multivariable logistic regression 
and Cox proportional hazard regression(simple and multiple) respectively. For multivariable analyses, we 
adjusted for date of first OAC prescription(relative to study start date), CHA2DS2VASc, HASBLED-1, 
Townsend Deprivation Index quintile and number of drugs. Optimal adjustments for CHA2DS2VASc, 
HASBLED-1, number of drugs and date of first OAC prescription were investigated using continuous 
variables(including potential quadratic effects) or clinically appropriate categorisation. Models were compared 
using Bayes Information Criterion(BIC) and the optimal model chosen based on lowest BIC.  For Cox 
regression, the proportional hazards assumption was investigated by adding interactions with ‘time in study’. 
Interactions were included if they improved the model(by BIC criterion). For non-adherence, a sensitivity 
analysis was performed in those who had ≥6 months’ potential OAC coverage(i.e. ≥6 months between date 
of first prescription and date of last prescription plus 30 days) and ≥12 months’ OAC potential coverage to 
reduce potential bias in estimated adherence in short treatment periods, leading to overestimate of PDC(Web 
Table 2(a) and 2(b)).  For non-persistence, two sensitivity analyses were based around the chosen Cox 
regression model by: (i)adding interactions(linear; linear and quadratic) between OAC and timing of first OAC 
prescription(relative to study initiation); and (ii)reclassifying those switching to another OAC as 
censored(cessation of observation) rather than non-persistent to first OAC prescribed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Among 4,354,740 individuals, 154,180 with AF were identified, of whom 36,652 met inclusion criteria for 
analysis: VKA(n=25,008, 68.2%), dabigatran(n=1285, 3.5%), rivaroxaban(n=5855, 16.0%) and 
apixaban(n=4504, 12.3%)(Figure 1). Major exclusions were no new AF diagnosis(n=95237) and absence of 
OAC prescription data(n=17065). Edoxaban was UK-approved in September 2015, leading to inadequate 
sample size for analysis(n=45) in the study period. 
The study population had mean) age 74.4(standard deviation 10.5) years and was 45% female. 
Cardiovascular comorbidities were common; hypertension(62.6%) and hypercholesterolaemia(71.8%), with 
median CHA2DS2VASc of 3(interquartile range, IQR 2-4). Polypharmacy was common(number of drugs: 
median 6, IQR 4-7). Individuals on dabigatran had lower CHA2DS2VASc scores, rates of hypertension and 
current smoking, with no other significant baseline differences across different OACs(Table 1). 
Adherence 
Adherence was 55.2%(54.6-55.7) overall, and 51.2%(50.6-51.8), 66.5%(63.7-69.2), 63.1%(61.8-64.4) and 
64.7(63.2-66.1) for VKA, dabigatran, rivaroxaban and apixaban respectively(Web Table 3).  
In univariable analysis, likelihood of non-adherence with DOACs was lower than with VKA(OR 0.53,0.47-
0.60; 0.61,0.58-0.65; and 0.57,0.54-0.61 for dabigatran, rivaroxaban and apixaban respectively)(Table 2 and 
Web Table 2(d)). In multivariable analysis, likelihood of non-adherence was similar for dabigatran(0.54,0.48-
0.62), but higher for rivaroxaban(0.76,0.71-0.82) and apixaban(0.77,0.71-0.84). Increasing comorbidity(by 
CHA2DS2VASc) was associated with decreased likelihood of non-adherence(1.00,0.93-1.08; 0.94,0.88-1.01 
and 0.81,0.74-0.89 for CHA2DS2VASc=2, 3-4 and 5-9 respectively, compared with CHA2DS2VASc=0-1), but 
not for HASBLED-1 score(0.98,0.93-1.05 for HASBLED-1≥3, compared with HASBLED-1 0-2). Number of 
drugs and Townsend quintile were not associated with non-adherence(Table 2). Age≥75 years, diabetes, 
female gender and anaemia were associated with reduced risk of non-adherence, while hypertension and 
vascular disease were associated with increased risk(Web Table 2(c)). Non-adherence was non-linearly 
associated with time since introduction of DOACs, increasing for approximately two years(to early 2013) 
before starting to decrease, returning to its original level by early 2015 (Web Figure 1(a))) and then dropping 
below its original level. Baseline characteristics by adherence status are in Web Table 4. Web Table 2(e) 
illustrates no important differences in the effect of time since introduction of DOACs between different OACs 
(Web Figure 1(b)). Sensitivity analysis in only those who had at least 6 or 12 months of OAC prescriptions 
showed little impact on relative non-adherence for dabigatran, and VKA; however estimated ORs for 
rivaroxaban and apixaban both decreased to 0.65(for 12-month restriction)(Web Tables 2(a) and (b)).  
Persistence 
One-year persistence was 65.9%(65.4-66.5) overall, and 63.4%(62.8-64.0), 61.4%(58.3-64.2), 72.3%(70.9-
73.7) and 78.7%(77.1-80.1) for VKA, dabigatran, rivaroxaban and apixaban respectively. Persistence 
reduced over three years for all OAC and was highest for apixaban and lowest for VKA and dabigatran(Figure 
2).  
In univariable analysis, apixaban had lowest(HR 0.53,0.50-0.57) and dabigatran had highest(HR 1.02,0.93-
1.11) risk of non-persistence at 1 year, relative to VKA. Table 3 illustrates the optimal multivariable model, 
where the effects of CHA2DS2VASc and OAC required an interaction term with time since first OAC 
prescription. The interaction between time and date of first prescription shows that immediately following first 
prescription, apixaban still had the lowest risk(0.53,0.46-0.60) and dabigatran the highest(1.24,1.08-1.42), 
relative to VKA. Risk of non-persistence did not change over time for apixaban(0.91,0.78-1.06 per year), but 
reduced over time for dabigatran(0.75,0.65-0.86 per year) and rivaroxaban(0.69,0.62-0.77 per year). 
Immediately after first prescription, increasing comorbidity, when measured by CHA2DS2VASc score, was 
associated with reduced risk of non-persistence(0.71,0.66-0.76; 0.66,0.62-0.71 and 0.69,0.63-0.76 for 
CHA2DS2VASc=2, 3-4 and 5-9 respectively, compared with CHA2DS2VASc=0-1). However, this risk was 
lessened over time(1.05,0.99-1.12 and 1.13,1.06-1.20 per year for CHA2DS2VASc=2 and 5-9 respectively). 
There was no significant effect of HASBLED-1(1.04,0.99-1.08 for HASBLED-1≥3, compared with HASBLED-
1 0-2), nor for number of drugs nor Townsend quintile(Table 3). Overall, risk of non-persistence increased 
from 2011 until 2016(1.03,1.01-1.05 per year). Heart failure, vascular disease, chronic kidney disease, prior 
bleeding and alcohol misuse were associated with increased risk of non-persistence, while hypertension and 
age>65 years were associated with reduced risk. Non-persistence was more likely for dabigatran soon after 
initiation, but the effect relative to VKA and to apixaban declined over the period of an individual’s prescription, 
although this did not happen relative to rivaroxaban(Web Table 5(a) and (b)). Baseline characteristics are 
presented by 1-year persistence status in Web Table 6.  
Persistence and adherence 
Of 36652 individuals, 31.0% had <1 year of data, and of these, 15.8% had primary non-adherence, 27.9% 
were non-adherent and 56.2% were adherent. Among 25263 individuals with ≥1 year of data, primary non-
adherence(3.5%) was less common than non-adherent, non-persistent(21.2%), adherent, non-
persistent(8.6%), non-adherent, persistent(26.5%) and persistent, adherent(40.2%). Differences between 
OACs were significant(p<0.001). Primary non-adherence was highest with dabigatran(7.8%)and 
lowest(2.7%) with apixaban, while persistent adherence was highest with apixaban(50.7%) and lowest with 
VKA (38.2%). Non-adherent, non-persistence was greatest with VKA(23.4%), and least with 
apixaban(12.4%). Non-adherent persistence was highest with apixaban(29.0%) and lowest with 
dabigatran(19.5%)(Table 4). 
Switching 
In non-persistent individuals, switching rates were 20.3%, 18.8%, 40.3%, 27.0% and 18.5% for all OACs, 
VKA, dabigatran, rivaroxaban and apixaban respectively. In primary non-adherent individuals, corresponding 
rates were 45.2%, 40.9%, 69.1%, 51.2% and 44.7% respectively(Web Table 7). When“switching” was 
censored rather than “non-persistent”, differences between OACs were more consistent over time(since first 
prescription) and non-persistence was generally lower for dabigatran than VKA, with an increasing trend in 
the difference with time on OAC. The effect was less for other DOACs relative to VKA(Web Fig 1 and Web 
Table 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion   
In this study of long-term persistence and adherence across all OACs in AF, we have four findings. First, 
primary non-adherence is uncommon(3.5%) and over time on a DOAC, likelihood of non-adherence and non-
persistence increases. Second, the proportion of individuals on OACs who are both adherent and persistent 
at 1 year is low(40.2%) with heterogeneity across different OACs. Third, population-level time trends in 
adherence and persistence exist after new drugs(DOACs in this case) are introduced. Fourth, increased 
comorbidities were associated with reduced risk of non-adherence and non-persistence for DOACs, but 
number of drugs was not.  
Observed rates of primary nonadherence for OAC are comparable to a recent Spanish study using large-
scale regional EHR(12). Primary nonadherence varies across different drugs but our estimates appear lower 
than other chronic disease medications(≤20.8% for lipid-lowering drugs(23)). Rates are generally lower in 
European populations(23) than in North America, probably due to greater provision of prescription medication 
in public-funded health systems. Our results suggest that improved adherence and persistence require 
longer-term monitoring, rather than current strategies emphasising drug adherence post-initiation. Greater 
switchingwith dabigatran than other OACs may reflect greater discontinuation(due to dyspepsia or other side-
effects(3)), or prescription patterns favouring other DOACs(24).      
For drugs to be effective, both adherence and persistence are prerequisites. It is therefore concerning that 
adherent persistence at 1 year after initial prescription ranged from only 38.2% to 50.7% for VKA and 
apixaban respectively. Non-adherent, non-persistent individuals constituted 23.4% and 12.4% for users of 
VKA and apixaban respectively(Table 4). Adherence and persistence should be considered in combination, 
yet this is rare in both research and clinical practice(25). Furthermore, observations that non-adherent, 
persistence is more common than adherent, non-persistence and that these proportions vary by type of OAC 
highlight need for measurement of both metrics and potential for personalising approaches to improved drug 
utilisation. Factors which influence choice of drug in the same class include pharmacodynamics, 
pharmacokinetic, tolerability and cost(26), to which adherence and persistence may be added.   
DOACs are unusual for several new drugs in the same class entering the market in a short timeframe. Other 
examples are statins, antihypertensives and novel hypoglycaemic agents, but four new drugs in a five-year 
period is extraordinary. DOACs have proven efficacy and effectiveness over VKA, and appropriate 
prescribing of OACs in AF has improved in the UK between 2000 and 2016(27). However, there have been 
variations in prescription across DOACs over time(28). Our analyses add that when DOACs were first 
prescribed, persistence to all DOACs appears to have been initially higher than to VKA and in some cases 
increase further over time on the OAC, with clear differences between different OACs. Findings were 
sensitive to how switched of drugs was considered, with persistence to dabigitran, which had highest rates 
of ‘switching’, appearing much lower than to VKA when ‘switchers’ were classed as ‘non-persistent’ versus 
censored( ‘no longer observed for that OAC’). Other possible reasons for differences between OACs include 
side effect profile, marketing strategies, and varying procurement and prescription practices. Adherence and 
persistence can have far-reaching implications on drug cost, effectiveness and policy at population level(29) 
and should be monitored at population level.  
Our findings are consistent with previous studies which have shown associations between polypharmacy(12, 
30) and increased comorbidities(25) and reduced risk of non-adherence or non-persistence for OACs and 
other cardiovascular medications. Understanding each of the multiple steps in the prescription-persistence 
cascade may aid design and implementation of better interventions to improve drug utilisation. In routine 
clinical practice, EHR-based methods may be used to highlight individuals at greater risk of non-adherence 
or non-persistence, e.g. by suggesting that persistence should be more of a focus for improvement than 
adherence, or for monitoring long-term adherence/persistence.  
The major strength of our analysis is consideration of the relationship between adherence and persistence 
together across all DOACs and VKA in the same population. As well as sociodemographic, health and 
medication characteristics, the influence of time was also analysed. Even in large-scale datasets with 
prescription data, there are several limitations. First, we did not have dispensing data, and therefore used 
previously validated methods to estimate adherence/persistence from prescription data. Our methods may 
be more uncertain for VKA than for DOACs(e.g. differential impact of varying prescription gaps on 
persistence), possibly due to patients on warfarin often having longer duration prescriptions than DOACs. 
Second, missing prescription data meant that not all eligible individuals could be included due to 
incompleteness of follow-up. On the other hand, these are real-world data, which are routinely available and 
nationally representative. Third, relatively small numbers of patients could be included for DOACs, but 
numbers were comparable with other studies. Fourth, TTR would be a better measure of adherence for VKA 
but could not be estimated in our analysis, due to lack of INR data(which also limited our HASBLED analysis). 
Finally, we focused on initial OAC prescription in OAC-naive patients to minimise bias in 
adherence/persistence based on previous OAC use, but did not focus on second and subsequent OACs 
used, where there would be more bias, and greater consideration of overall treatment pattern which requires 
consideration of multi-drug, multi-disease adherence/persistence over time. 
Conclusions 
Our study shows changes in adherence and persistence for DOACs over time in AF. Since these are usually 
lifelong therapies, more emphasis should be placed on long-term adherence and persistence in clinical 
practice and research. Standardisation is required for EHR methods of adherence and persistence estimation 
across drugs, diseases and datasets. Persistence and adherence may have different determinants and 
should be studied together in EHR. Better understanding of these factors will lead to interventions which are 
more likely to improve adherence and persistence at individual and population levels across OACs and other 
drugs. Post-marketing surveillance should take into account adherence and persistence particularly for 
multiple drugs in the same class where head-to-head trials are unlikely. 
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Table 1. Baseline characteristics of study population. 
 Overall 
(N=36,652) 
VKA  
(n=25,008)  
Dabigatran 
(n=1,285) 
Rivaroxaban 
(n=5,855) 
Apixaban 
(n=4,504) 
P 
Characteristic [n(%)]       
Age [Mean(SD)] 74.4(10.5) 74.3 (10.2) 73.4(11.2) 74.8(11.0) 74.8(11.0) <0.001 
Female  16,494(45.0) 11,186(44.7) 517(40.2) 2,671(45.6) 2,120(47.1) <0.001 
Townsend Quintile [Median(IQR)] 2(1-4) 2(1-4) 2(1-3) 3(1-4) 3(1-4)  
  1  8,862(24.2) 6,124(24.5) 345(26.9) 1,347(23.0) 1,046(23.2) 
<0.001 
  2  8,269(22.6) 5,706(22.8) 321(25.0) 1,300(22.2) 942(20.9) 
  3  7,330(20.0) 4,964(19.9) 270(21.0) 1,231(21.0) 865(19.2) 
  4  5,864(16.0) 4,065(16.3) 185(14.4) 897(15.3) 717(15.9) 
  5  3,800(10.4) 2,540(10.2) 98(7.6) 574(9.8) 588(13.1) 
  Missing  2,527(6.9) 1,609(6.4) 66(5.1) 506(8.6) 346(7.7)  
COMORBIDITIES [n(%)]       
Heart failure 2,700(7.4) 1,908 (7.6) 79(6.2) 387(6.6) 326(7.2) 0.016 
Hypertension 22,955(62.6) 15,824(63.3) 751(58.4) 3,612(61.7) 2,768(61.5) <0.001 
Diabetes mellitus 6,691(18.3) 4,594(18.4) 210(16.3) 1,058(18.1) 829(18.4) 0.31 
Stroke/TIA 4,622(12.6) 3,096(12.4) 160(12.5) 735(12.6) 631(14.0) 0.026 
Vascular disease 4,793(13.1) 3,316(13.3) 149(11.6) 717(12.3) 611(13.6) 0.052 
Alcohol misuse 977(2.7) 589(2.4) 36(2.8) 175(3.0) 177(3.9) <0.001 
CKD 7,844(21.4) 5,426(21.7) 221(17.2) 1,229(21.0) 968(21.5) 0.002 
Liver disease 100(0.3) 67(0.3) 4(0.3) 15(0.3) 14(0.3) 0.94 
Hypercholesterolaemia 26,328(71.8) 17,979(71.9) 915(71.2) 4,172(71.3) 3,262(72.4) 0.56 
Smoking Status       
  Current smoker  3,374(9.2) 2,272(9.1) 103(8.0) 585(10.0) 414(9.2) 
<0.001 
  Ex-smoker  13,928(38.0) 9,711(38.8) 484(37.7) 2,125(36.3) 1,608(35.7) 
  Never smoked  18,484(50.4) 12,472(49.9) 666(51.8) 2,993(51.1) 2,353(52.2) 
  Not indicated  866(2.4) 553(2.2) 32(2.5) 152(2.6) 129(2.9) 
RISK SCORES [n(%)]       
  CHA2DS2-VASc         
    [0-1] 5,856(16.0) 3,887(15.5) 263(20.5) 984(16.8) 722(16.0) 
<0.001 
    [2] 7,192(19.6) 4,939(19.8) 279(21.7) 1,106(18.9) 868(19.3) 
    [3-4] 17,894(48.8) 12,324(49.3) 571(44.4) 2,850(48.7) 2,149(47.7) 
    [5-9] 5,710(15.6) 3,858(15.4) 172(13.4) 915(15.6) 765(17.0) 
  HASBLED-1         
    [0-2] 28,279(77.2) 19,298(77.2) 1,047(81.5) 4,508(77.0) 3,426(76.1) 
<0.001 
    [3-8] 8,373(22.8) 5,710(22.8) 238(18.5) 1,347(23.0) 1,078(23.9) 
DRUGS [n(%)]       
Aspirin 20,510(56.0) 14,175(56.7) 683(53.2) 3,116(53.2) 2,536(56.3) <0.001 
Statin 17,185(46.9) 11,803(47.2) 551(42.9) 2,651(45.3) 2,180(48.4) <0.001 
BP-lowering drugs 29,136(79.5) 20,007(80.0) 961(74.8) 4,563(77.9) 3,605(80.0) <0.001 
Number of Drugs [Mean(SD)] 5.5(2.2) 5.5(2.2) 5.3(2.2) 5.5(2.2) 5.7(2.2) <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Table 2 Likelihood of non-adherence by oral anticoagulant. 
Odds ratios (95% CI)  Univariable Multivariable  
N 33,960 31,615 P-value 
VKA 1.00 (-) 1.00 (-)  
Dabigatran 0.53 (0.47 to 
0.60) 
0.54 (0.48 to 0.62) 
<0.001 
Rivaroxaban 0.61 (0.58 to 
0.65) 
0.76 (0.71 to 0.82) 
Apixaban 0.57 (0.54 to 
0.61) 
0.77 (0.71 to 0.84) 
CHA2DS2Vasc    
    [0,1]  1.00 (-)  
    [2]  1.00 (0.93 to 1.08) 
<0.001     [3,4]  0.94 (0.88 to 1.01)  
    [5,9]  0.81 (0.74 to 0.89) 
HASBLED-1    
    [0,2]  1.00 (-)  
    [3,9]  0.98 (0.93 to 1.05) 0.62 
Number of drugs    
  Continuous/ 
  Linear 
 
0.99 (0.98 to 1.00) 0.067 
Townsend Quintile    
  [1]  1.00 (-)  
  [2]  0.93 (0.87 to 0.99) 
<0.001 
  [3]  0.86 (0.80 to 0.91) 
  [4]  0.91 (0.85 to 0.97) 
  [5]  0.86 (0.80 to 0.94) 
Date of first prescriptiona (years after 1st January 2011)    
  Continuous/ 
  Linear 
 1.29 (1.22 to 1.37) 
<0.001 
  Continuous/ 
  Quadratic 
 0.94 (0.93 to 0.95) 
BIC 46263.63 42880.41  
a Time difference (in years) between the date of the first ever OAC prescription for each patient and the start date of the study (1st January 2011).This 
suggests that the maximum effect of calendar time occurs at -ln(1.29)(2*/ln(0.94))=2.13 years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Risk of non-persistence by oral anticoagulant. 
 
Hazard ratios (95% CI)  Univariable Multivariable 
N 36,636 34,109 
OAC (effect on first prescribing)   
    VKA 1.00 (-) 1.00 (-) 
    Dabigatran 1.02 (0.93 to 1.11) 1.24 (1.08 to 1.42) 
    Rivaroxaban 0.71 (0.67 to 0.74) 0.85 (0.77 to 0.93) 
    Apixaban 0.53 (0.50 to 0.57) 0.53 (0.46 to 0.60) 
Time-dependent effect of OAC (per year of 
prescriptions) 
  
    VKA  1.00 (-) 
    Dabigatran  0.75 (0.65 to 0.86) 
    Rivaroxaban  0.69 (0.62 to 0.77) 
    Apixaban  0.91 (0.78 to 1.06) 
CHA2DS2Vasc  (effect on first prescribing)   
    [0-1]  1.00 (-) 
    [2]  0.71 (0.66 to 0.76) 
    [3,4]  0.66 (0.62 to 0.71) 
    [5,9]  0.69 (0.63 to 0.76) 
Time-dependent effect of CHA2DS2Vasc (per year of 
prescriptions) 
  
    [0,1]  1.00 (-) 
    [2]  1.05 (0.99 to 1.12) 
    [3,4]  1.12 (1.07 to 1.18) 
    [5,9]  1.13 (1.06 to 1.20) 
HASBLED-1   
    [0,2]  1.00 (-) 
    [3,9]  1.04 (0.99 to 1.08) 
Number of drugs  1.00 (0.99 to 1.01) 
Townsend Quintile   
   [1]  1.00 (-) 
   [2]  0.99 (0.95 to 1.03) 
   [3]  0.95 (0.91 to 1.00) 
   [4]  0.97 (0.93 to 1.02) 
   [5]  0.97 (0.92 to 1.03) 
Date of first prescription a (years after 1`st January 
2011) 
 1.03 (1.02 to 1.05) 
a Time difference (in years) between the date of the first ever OAC prescription for each patient and the start date of the study (1st January 2011) . 
b Time-dependent covariates are interacted with survival analysis time (e.g. time on a specific OAC), i.e. (end date of persistence or exit from/end of study - 
date of first ever OAC prescription)/365.25. 
  
Table 4. Adherence and persistence by oral anticoagulant. 
 
 Overall VKA Dabigatran Rivaroxaban Apixaban 
Total [n(%)] 36652 25008 1285 5855 4504 
Zero follow-up  16(0.04) 7(0.03) 1(0.08) 5(0.09) 3(0.07) 
Total <1 yr of data 11373(31.0) 5307(21.2) 441(34.3) 3,014 (51.5) 2,611(58.0) 
Primary non-adherence 1,800(15.8) 818(15.4) 78(17) 531(17.6) 373(14.3) 
Non-adherent 3178(27.9) 1,654(31.2) 94(21.3) 771(25.6) 659(25.2) 
Adherent 6,395(56.2) 2,835(53.4) 269(61.0) 1,712(56.8) 1,579(60.5) 
Total ≥1 yr of data 25,263(68.9) 19694(78.8) 843(65.6) 2,836(48.4) 1,890(42.0) 
Primary non-adherence 876(3.5) 631(3.2) 66(7.8) 128(4.5) 51(2.7) 
Non-adherent, non-persistent 5,352 (21.2) 4,616(23.4) 124(14.7) 378(13.3) 234(12.4) 
Adherent, non-persistent 2,173 (8.6) 1711(8.7) 132(15.7) 232(8.2) 98 (5.2) 
Non-adherent, persistent 6,699 (26.5) 5221(26.5) 164(19.5) 766(27.0) 548 (29.0) 
Persistent, adherent 10,163 (40.2) 7515(38.2) 357(42.3) 1,332(47.0) 959 (50.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
